申请人:ZENECA LIMITED
公开号:EP0586229A1
公开(公告)日:1994-03-09
The invention concerns pyrrolidine derivatives of the formula I
wherein Ar¹ is optionally-substituted phenyl, naphthyl or a 10-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur;
A is a direct link to the group X or A is (1-4C)alkylene;
X is oxy, thio, sulphinyl or sulphonyl;
Ar² is phenylene, pyridinediyl, pyrimidinediyl, thiophendiyl, furandiyl or thiazolediyl;
R¹ is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl;
R² is (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, halogeno-(1-4C)alkyl, halogeno-(2-4C)alkenyl, halogeno-(2-4C)alkynyl,
(1-4C)alkoxy-(2-4C)alkyl, hydroxy-(2-4C)alkyl, cyano-(1-4C)alkyl, carboxy-(1-4C)alkyl, carbamoyl-(1-4C)alkyl,
(1-4C)alkoxycarbonyl-(1-4C)alkyl, N-(1-4C)alkylcarbamoyl-(1-4C)alkyl or N,N-di-(1-4C)alkylcarbamoyl-(1-4C)alkyl; and
n is 1 or 2 and each R³ is independently hydrogen, hydroxy, (1-4C)alkyl or (1-4C)alkoxy;
or a pharmaceutically-acceptable salt thereof;
processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.
本发明涉及式 I 的
吡咯烷衍
生物
其中 Ar¹ 是任选取代的
苯基、
萘基或含有一个或两个
氮杂原子并任选含有另一个选自
氮、
氧和
硫的杂原子的 10 元双环杂环分子;
A 是与基团 X 的直接连接,或 A 是(1-4C)亚烷基;
X 是
氧、
硫、亚
硫酰或磺酰;
Ar² 是亚
苯基、
吡啶二基、
嘧啶二基、
噻吩二基、
呋喃二基或
噻唑二基;
R¹ 是(1-4C)烷基、(3-4C)
烯基或(3-4C)炔基;
R²是(1-4C)烷基、(2-4C)
烯基、(2-4C)炔基、卤代-(1-4C)烷基、卤代-(2-4C)
烯基、卤代-(2-4C)炔基、
(1-4C)烷
氧基-(2-4C)烷基、羟基-(2-4C)烷基、
氰基-(1-4C)烷基、羧基-(1-4C)烷基、
氨基甲酰基-(1-4C)烷基、
(1-4C)烷
氧基羰基-(1-4C)烷基、N-(1-4C)烷基
氨基甲酰基-(1-4C)烷基或
N,N-二(1-4C)烷基
氨基甲酰基-(1-4C)烷基;以及
n为1或2,且每个R³独立地为
氢、羟基、(1-4C)烷基或(1-4C)烷
氧基;
或其药学上可接受的盐;
它们的制造工艺;含有它们的药物组合物以及它们作为 5-脂
氧合酶
抑制剂的用途。